Израиль - английский - Ministry of Health

teva medical ltd - calcium chloride; glucose hydrous; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - glucose hydrous 1.5 g / 100 ml; calcium chloride 18.3 mg / 100 ml; sodium chloride 538 mg / 100 ml; lactic acid as sodium 448 mg / 100 ml; magnesium chloride 5.08 mg / 100 ml - combinations of electrolytes - combinations of electrolytes - for use in chronic renal failure patients being maintained in peritoneal dialysis.

Израиль - английский - Ministry of Health

teva medical ltd - calcium chloride; glucose hydrous; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - glucose hydrous 2.5 g / 100 ml; calcium chloride 18.3 mg / 100 ml; sodium chloride 538 mg / 100 ml; lactic acid as sodium 448 mg / 100 ml; magnesium chloride 5.08 mg / 100 ml - combinations of electrolytes - combinations of electrolytes - for use in chronic renal failure patients being maintained in peritoneal dialysis.

Израиль - английский - Ministry of Health

teva medical ltd - calcium chloride; glucose hydrous; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - glucose hydrous 4.25 g / 100 ml; magnesium chloride 5.08 mg / 100 ml; sodium chloride 538 mg / 100 ml; lactic acid as sodium 448 mg / 100 ml; calcium chloride 18.3 mg / 100 ml - electrolytes in combination with other drugs - electrolytes in combination with other drugs - for use in chronic renal failure patient being maintained in peritoneal dialysis.

Сингапур - английский - HSA (Health Sciences Authority)

good pharmaceutical pte. ltd. - epinephrine - injection - 1.10mg/ml (includes a 10% overage) - epinephrine 1 mg/ml

Сингапур - английский - HSA (Health Sciences Authority)

good pharmaceutical pte. ltd. - epinephrine - injection - 0.55mg/ml (includes a 10% overage) - epinephrine 0.5 mg/ml

Австралия - английский - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 135 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; sucrose; polysorbate 80; methionine; disodium edetate; water for injections; histidine - crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - adrenaline (epinephrine), quantity: 0.15 mg - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; hydrochloric acid; water for injections - for the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, or bites, foods, drugs or other allergens.

Соединенные Штаты - английский - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 100 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

Соединенные Штаты - английский - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 75 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

Соединенные Штаты - английский - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 25 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa